🤖 Verge Genomics: Using AI to discover new drugs
Using AI and human data to develop better drugs faster
It takes an average of 10 years to develop a potential new medicine – largely due to the complexities of deciphering biological data. This week’s AI company Verge Genomics uses AI to disrupt the drug industry.
⚾ The Elevator Pitch:
In biopharma, the cost of developing a drug continues to multiply. Despite decades of work from millions of scientists, deciphering biological complexity remains one of the greatest challenges and largest opportunities for humanity.
Verge Genomics employs AI and human data to develop better drugs faster for the most challenging diseases of our generation
👇 The drop down
Stage: Series B
Team: Alice Zhang
Traction: Blackrock and YC backed, $98m in series B
🔍 Why we like it
🧠 Targeting an important and rapidly growing industry
US national healthcare expenditure reached $4.1T in 2020. If there is one thing that the pandemic has shown us, strong and efficient healthcare systems are important. Verge targets this space using AI to create better drugs faster.
📈 Accelerating novel drugs and cures
Verge Genomic’s proprietary platform ConVERGE allows them to quickly and efficiently discover novel targets and develop clinical candidates in-house.This means a much faster research to clinical candidate timeline compared to competitors.
😤 New discoveries and trials as we speak
Verge already has their ALS PIKFYVE in clinical trials. Their other programs are also steadily jumping through their hoops, including their Parkinson’s disease progrma.
🤝 Get involved with Verge Genomics
Read more about their pipeline here